全文获取类型
收费全文 | 929篇 |
免费 | 84篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 92篇 |
妇产科学 | 19篇 |
基础医学 | 99篇 |
口腔科学 | 19篇 |
临床医学 | 148篇 |
内科学 | 271篇 |
皮肤病学 | 8篇 |
神经病学 | 46篇 |
特种医学 | 135篇 |
外科学 | 44篇 |
综合类 | 27篇 |
预防医学 | 40篇 |
眼科学 | 7篇 |
药学 | 63篇 |
中国医学 | 1篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 4篇 |
2022年 | 8篇 |
2021年 | 4篇 |
2020年 | 6篇 |
2019年 | 12篇 |
2018年 | 20篇 |
2017年 | 7篇 |
2016年 | 14篇 |
2015年 | 18篇 |
2014年 | 29篇 |
2013年 | 33篇 |
2012年 | 25篇 |
2011年 | 24篇 |
2010年 | 36篇 |
2009年 | 34篇 |
2008年 | 31篇 |
2007年 | 50篇 |
2006年 | 23篇 |
2005年 | 23篇 |
2004年 | 26篇 |
2003年 | 31篇 |
2002年 | 24篇 |
2001年 | 18篇 |
2000年 | 26篇 |
1999年 | 29篇 |
1998年 | 53篇 |
1997年 | 38篇 |
1996年 | 43篇 |
1995年 | 29篇 |
1994年 | 19篇 |
1993年 | 25篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1990年 | 24篇 |
1989年 | 38篇 |
1988年 | 40篇 |
1987年 | 27篇 |
1986年 | 27篇 |
1985年 | 20篇 |
1984年 | 14篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1977年 | 12篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1967年 | 2篇 |
排序方式: 共有1058条查询结果,搜索用时 15 毫秒
1.
2.
3.
M P Diamond M L Polan M Blanchette C M Mazure A H DeCherney B Lunenfeld 《Gynecological endocrinology》1992,6(2):135-139
A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (#03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 +/- 130; A2, 700 +/- 107; B, 520 +/- 80 pg/ml, analysis of variance p greater than 0.5) and on Day 9 (A1, 1051 +/- 144; A2, 1140 +/- 155; B, 840 +/- 124 pg/ml, p greater than 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (greater than or equal to 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 +/- 0.9; A2, 4.0 +/- 0.7; B, 4.5 +/- 0.9, p greater than 0.05; Day 9: total A1, 6.7 +/- 0.9; A2, 6.9 +/- 0.8; B, 6.9 +/- 0.9, p greater than 0.05) in all three cycles were also similar.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
5.
6.
Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma 总被引:3,自引:4,他引:3
Botchan A; Hauser R; Gamzu R; Yogev L; Lessing JB; Paz G; Yavetz H 《Human reproduction (Oxford, England)》1997,12(1):73-76
The study was conducted to determine the deleterious effect of lymphoma
disease on spermatogenesis and to evaluate the possibility that the disease
is mediated primarily by inherent mechanisms in Hodgkin's disease and
non-Hodgkin's lymphoma patients. A total of 89 patients with lymphoma
disease (Hodgkin's and non-Hodgkin's) were referred for sperm preservation
prior to adjuvant treatments. A comparison was made of pre- and post-thaw
sperm quality between lymphoma patients and healthy volunteers who applied
for sperm donation. This was followed by further assessment of the
differences between patients with Hodgkin's disease and non-Hodgkin's
lymphoma in terms of sperm variables, clinical parameters and blood hormone
concentrations. It was found that patients with lymphoma disease had
significantly impaired pre-freeze and post-thaw sperm quality compared with
that of healthy volunteers. Patients with non-Hodgkin's lymphoma had
spermatozoa of higher quality than patients with Hodgkin's disease. No
differences were found in the clinical or hormonal parameters between these
two groups. As expected, reduced testicular size and abnormal testicular
consistency were correlated with decreased sperm quality. The mere presence
of cancer disease has a direct negative effect on spermatogenesis, which is
probably not related to incidental side-effects. A variable degree of
impairment should be expected with different categories of cancer.
相似文献
7.
Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance 总被引:10,自引:0,他引:10
Curb JD Rodriguez BL Abbott RD Petrovitch H Ross GW Masaki KH Foley D Blanchette PL Harris T Chen R White LR 《Neurology》1999,52(5):971-975
OBJECTIVE: To assess the relationship between impaired glucose tolerance and both vascular dementia and AD. BACKGROUND: Diabetes and abnormalities of glucose metabolism have been associated with stroke and poor cognitive function. In addition, glycoproteins and glycosylation have been postulated to be associated with the development of neuritic plaques characteristic of AD. METHODS: A historical prospective cohort study of Japanese-American men (n = 3,774), who were examined at ages 45 to 68 (1965 through 1968) and again at ages 71 to 93 (1991 through 1993). Measurements were obtained by clinical and home examinations: assessment of glucose intolerance (nonfasting 1 hour after glucose load) from 1965 through 1968 and history of diabetes diagnosed by a physician at examinations given from 1965 through 1968 and from 1976 through 1978. At the 1991 through 1993 examinations, the Cognitive Assessment Screening Instrument (CASI)-an instrument designed for use in cross-cultural settings combining features of the Folstein Mini-Mental State Examination, the Modified Mini-Mental State Examination, and the Hasegawa Dementia Screening Scale-was used. Diagnosis and classification of AD and vascular dementia were made by a consensus panel using neuropsychologic assessment data, a neurologist's evaluation, and information from a family informant. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised criteria were used to establish dementia, and subclassification by cause was based on other published criteria. RESULTS: No association between AD and diabetes, present either 25 or 15 years previously, was found after adjustment for age and education in a multiple regression model. A significant association was found between impaired glucose tolerance at baseline and vascular dementia (p < 0.01). CONCLUSIONS: These findings confirm expected relationships between impaired glucose tolerance and stroke-related dementia but do not support an association of disordered glucose metabolism with AD. 相似文献
8.
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. 总被引:6,自引:0,他引:6
9.
10.
BACKGROUND: The goal of this study was to assess variations with age in the management of breast carcinoma and to identify determinants of care received. METHODS: A stratified random sample was selected among women age > or = 50 newly diagnosed with lymph node negative breast carcinoma in Quebec in 1988, 1991, and 1993. Information was abstracted from medical charts. Predictors of definitive locoregional treatment (total mastectomy with lymph node dissection or breast-conserving surgery with both axillary lymph node dissection and radiation therapy) were identified by multiple logistic regression analysis. RESULTS: Overall, 1174 patients age > or = 50 years with breast carcinoma were included. Women age > or = 70 years were much less likely to receive definitive locoregional treatment compared with women ages 50-69 years (48.7% vs. 83.5%; P < 0.0001). Older women were less likely to undergo surgery with breast preservation (76.7% vs. 86.3%; P < 0.0001), radiation therapy (54.7% vs. 90.5%; P < 0.0001), dissection of the axillary lymph nodes (55.6% vs. 86.3%; P < 0.0001), or chemotherapy (1.2% vs. 13.9%; P < 0.0001), but not treatment with tamoxifen (66.4% vs. 64.7%; P = 0.41). Adjusting for comorbidity and other characteristics related to the disease, the hospital, and the attending physician, age remained a strong determinant of the probability of receiving definitive locoregional treatment (odds ratio [OR], 0.14; 95% confidence interval [95% CI], 0.12-0.18 for women age > or = 70 years vs. women ages 50-69 years). The same association was observed when women who did not undergo lymph node dissection but who received systemic adjuvant treatment were considered to have received definitive therapy (OR, 0.13; 95% CI, 0.10-0.17) for women age > or = 70 years vs. women ages 50-69 years). CONCLUSIONS: Less aggressive patterns of care are provided to elderly breast carcinoma patients, independent of comorbidity. This could explain, at least in part, the sustained breast carcinoma mortality in this population. 相似文献